TOP TEN perturbations for 1492_f_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1492_f_at
Selected probe(set): 1494_f_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1492_f_at (1494_f_at) across 6672 perturbations tested by GENEVESTIGATOR:

hepatoblastoma study 1 (NOS) / normal liver tissue

Relative Expression (log2-ratio):-6.192831
Number of Samples:5 / 5
Experimental hepatoblastoma study 1 (NOS)
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue

Relative Expression (log2-ratio):-6.1905384
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (mixed epithelial and mesenchymal)
Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (epithelial mixed) / normal liver tissue

Relative Expression (log2-ratio):-6.158662
Number of Samples:12 / 5
Experimental hepatoblastoma study 1 (epithelial mixed)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (crowded fetal) / normal liver tissue

Relative Expression (log2-ratio):-6.1331987
Number of Samples:3 / 5
Experimental hepatoblastoma study 1 (crowded fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); crowded fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (fetal) / normal liver tissue

Relative Expression (log2-ratio):-5.833992
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):-5.6713476
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-5.568857
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-5.290289
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

hepatoblastoma study 1 (mixed embryonal and fetal) / normal liver tissue

Relative Expression (log2-ratio):-4.9212484
Number of Samples:13 / 5
Experimental hepatoblastoma study 1 (mixed embryonal and fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); mixed embryonal and fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 9 (HBV) / normal liver tissue

Relative Expression (log2-ratio):-4.826268
Number of Samples:10 / 10
Experimental HCC study 9 (HBV)
Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

Organism: Homo sapiens
Gene: 1492_f_at
Selected probe(set): 207244_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1492_f_at (207244_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

hepatoblastoma study 1 (NOS) / normal liver tissue

Relative Expression (log2-ratio):-5.2367315
Number of Samples:5 / 5
Experimental hepatoblastoma study 1 (NOS)
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (fetal) / normal liver tissue

Relative Expression (log2-ratio):-5.1809826
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (epithelial mixed) / normal liver tissue

Relative Expression (log2-ratio):-5.068513
Number of Samples:12 / 5
Experimental hepatoblastoma study 1 (epithelial mixed)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (crowded fetal) / normal liver tissue

Relative Expression (log2-ratio):-5.056429
Number of Samples:3 / 5
Experimental hepatoblastoma study 1 (crowded fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); crowded fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue

Relative Expression (log2-ratio):-4.9498987
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (mixed epithelial and mesenchymal)
Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):-4.7313423
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-4.5878315
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-4.3174744
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):-4.24749
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

HCC study 26 (tumor; TG/GG genotype) / HCC study 26 (non-tumor; TG/GG genotype)

Relative Expression (log2-ratio):-4.1679354
Number of Samples:10 / 10
Experimental HCC study 26 (tumor; TG/GG genotype)
Liver tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).
Control HCC study 26 (non-tumor; TG/GG genotype)
Liver non-tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).